The expression profiles of the galectin gene family in primary and metastatic papillary thyroid carcinoma with particular emphasis on galectin-1 and galectin-3 expression

Experimental and Molecular Pathology

Volumn 96, Issue 2, 2014, Pages 212-218

  Salajegheh, Ali ^a   Dolan Evans, Elliot ^a   Sullivan, Emily ^a   Irani, Soussan ^a   Rahman, Md Atiqur ^a   Vosgha, Haleh ^a   Gopalan, Vinod ^a   Smith, Robert Anthony ^a   Lam, Alfred King Yin ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Galectin; Galectin 1; Galectin 3; Papillary thyroid carcinoma

Indexed keywords

ECALECTIN; GALECTIN; GALECTIN 1; GALECTIN 10; GALECTIN 12; GALECTIN 2; GALECTIN 3; GALECTIN 4; GALECTIN 7; GALECTIN 8; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; GALECTIN 1 GENE; GALECTIN 10 GENE; GALECTIN 12 GENE; GALECTIN 2 GENE; GALECTIN 3 GENE; GALECTIN 4 GENE; GALECTIN 7 GENE; GALECTIN 8 GENE; GALECTIN 9 GENE; GENE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; THYROID CARCINOMA; ADULT; AGED; BIOSYNTHESIS; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; THYROID TUMOR;

ADULT; AGED; CARCINOMA; FEMALE; GALECTIN 1; GALECTIN 3; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RNA, MESSENGER; THYROID NEOPLASMS;

EID: 84896699932     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2014.02.003     Document Type: Article

References (45)

1. Balan V., Nangia-Makker P., Raz A. Galectins as cancer biomarkers. Cancers (Basel) 2010, 20(2):592-610.
2. Banh A., Zhang J., Cao H., Bouley D.M., Kwok S., Kong C., Giaccia A.J., Koong A.C., Le Q.T. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res. 2011, 71:4423-4431.
3. Beesley M.F., McLaren K.M. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology 2002, 41:236-243.
4. Bernet V.J., Anderson J., Vaishnav Y., Solomon B., Adair C.F., Saji M., Burman K.D., Burch H.B., Ringel M.D. Determination of galectin-3 messenger ribonucleic acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. J. Clin. Endocrinol. Metab. 2002, 87:4792-4796.
5. Brown L.M., Helmke S.M., Hunsucker S.W., Netea-maier R.T., Chiang S.A., Heinz D.E., Shroyer K.R., Duncan M.W., Haugen B.R. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol. Carcinog. 2006, 45:613-626.
6. Camby I., Le Mercier M., Lefranc F., Kiss R. Galectin-1: a small protein with major functions. Glycobiology 2006, 16:137R-157R.
7. Chiariotti L., Salvatore P., Frunzio R., Bruni C.B. Galectin genes: regulation of expression. Glycoconj. J. 2004, 19:441-449.
8. Cvejic D., Savin S., Petrovic I., Paunovic I., Tatic S., Krgovic K., Havelka M. Galectin-3 expression in papillary microcarcinoma of the thyroid. Histopathology 2005, 47:209-214.
9. Cvejic D.S., Savin S.B., Petrovic I.M., Paunovic I.R., Tatic S.B., Havelka M.J. Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size. Head Neck 2005, 27:1049-1055.
10. Dumic J., Dabelic S., Flögel M. Galectin-3: an open-ended story. Biochim. Biophys. Acta 2006, 1760:616-635.
11. Feilchenfeldt J., Tötsch M., Sheu S.-Y., Robert J., Spiliopoulos A., Frilling A., Schmid K.W., Meier C.A. Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry. Mod. Pathol. 2003, 16:1117-1123.
12. Hayashi T., Saito T., Fujimura T., Hara K., Takamochi K., Mitani K., Mineki R., Kazuno S., Oh S., Ueno T., Suzuki K., Yao T. Galectin-4, a novel predictor for lymph node metastasis in lung adenocarcinoma. PLoS One 2013, 10(8):e81883.
13. Htwe T.T., Karim N., Wong J., Jahanfar S., Mansur M.A. Differential expression of galectin-3 in advancing thyroid cancer cells: a clue toward understanding tumour progression and metastasis. Singap. Med. J. 2010, 51:856-859.
14. Inohara H., Honjo Y., Yoshii T., Akahani S., Yoshida J., Hattori K., Okamoto S., Sawada T., Raz A., Kubo T. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 1999, 85:2475-2484.
15. Irie A., Yamauchi A., Kontani K., Kihara M., Liu D., Shirato Y., Seki M., Nishi N., Nakamura T., Yokomise H., Hirashima M. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin. Cancer Res. 2005, 11:2962-2968.
16. Ito K., Stannard K., Gabutero E., Clark A.M., Neo S.Y., Onturk S., Blanchard H., Ralph S.J. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev. 2012, 31:763-778.
17. Iurisci I., Tinari N., Natoli C., Angelucci D., Cianchetti E., Iacobelli S. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin. Cancer Res. 2000, 6:1389-1393.
18. Jung J.H., Kim H.J., Yeom J., Yoo C., Shin J., Yoo J., Kang C.S., Lee C. Lowered expression of galectin-2 is associated with lymph node metastasis in gastric cancer. J. Gastroenterol. 2012, 47:37-48.
19. Kawachi K., Matsushita Y., Yonezawa S., Nakano S., Shirao K., Natsugoe S., Sueyoshi K., Aikou T., Sato E. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum. Pathol. 2000, 31:428-433.
20. Kim E.S., Lim D.J., Lee K., Jung C.K., Bae J.S., Jung S.L., Baek K.H., Lee J.M., Moon S.D., Kang M.I., Cha B.Y., Lee K.W., Son H.Y. Absence of galectin-3 immunostaining in fine-needle aspiration cytology specimens from papillary thyroid carcinoma is associated with favorable pathological indices. Thyroid 2012, 22:1244-1250.
21. Kim S.J., Hwang J.A., Ro J.Y., Lee Y.S., Chun K.H. Galectin-7 is epigenetically-regulated tumor suppressor in gastric cancer. Oncotarget 2013, 4:1461-1471.
22. Kim H.J., Do I.G., Jeon H.K., Cho Y.J., Park Y.A., Choi J.J., Sung C.O., Lee Y.Y., Choi C.H., Kim T.J., Kim B.G., Lee J.W., Bae D.S. Galectin-1 expression is associated with tumor invasion and metastasis in stage IB to IIA cervical cancer. Hum. Pathol. 2013, 44:62-68.
23. Lam A.K., Lo C.Y., Lam K.S. Papillary carcinoma of thyroid: a 30-yr clinicopathological review of the histological variants. Endocr. Pathol. 2005, 16:323-330.
24. Liang M., Ueno M., Oomizu S., Arikawa T., Shinonaga R., Zhang S., Yamauchi A., Hirashima M. Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2008, 134:899-907.
25. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods 2001, 25:402-408.
26. Mehrotra P., Okpokam a, Bouhaidar R., Johnson S.J., Wilson J.a, Davies B.R., Lennard T.W. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 2004, 45:493-500.
27. Newlaczyl A.U., Yu L.G. Galectin-3-a jack-of-all-trades in cancer. Cancer Lett. 2011, 313:123-128.
28. Oestreicher-Kedem Y., Halpern M., Roizman P., Hardy B., Sulkes J., Feinmesser R., Stern Y. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions. Head Neck 2004, 26:960-966.
29. Orlandi F., Saggiorato E., Pivano G., Puligheddu B., Termine A., Cappia S., De Giuli P., Angeli A. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res. 1998, 3015-3020.
30. Pantanowitz L., Balogh K. Charcot-Leyden crystals: pathology and diagnostic utility. Ear Nose Throat J. 2004, 83:489-490.
31. Rabinovich G.A. Galectin-1 as a potential cancer target. Br. J. Cancer 2005, 92:1188-1192.
32. Rorive S., Eddafali B., Fernandez S., Decaestecker C., André S., Kaltner H., Kuwabara I., Liu F.T., Gabius H.J., Kiss R., Salmon I. Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications. Mod. Pathol. 2002, 15:1294-1301.
33. Salajegheh A., Smith R.A., Kasem K., Gopalan V., Nassiri M.R., William R., Lam A.K. Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes. Eur. J. Surg. Oncol. 2011, 37:93-99.
34. Saussez S., Glinoer D., Chantrain G., Pattou F., Carnaille B., Andre S., Gabius H.J., Laurent G. Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid 2008, 18:705-712.
35. Savin S., Cvejić D., Janković M., Isić T., Paunović I., Tatić S. Evaluation of galectin-8 expression in thyroid tumors. Med. Oncol. 2009, 26:314-318.
36. Sobin L., Wittekind C. International Union against Cancer (UICC) TNM Classification of Malignant Tumours 2009, Springer Press, Berlin. 7th ed.
37. Takano T., Miyauchi A., Matsuzuka F., Yoshida H., Kuma K., Amino N. Ubiquitous expression of galectin-3 mRNA in benign and malignant thyroid tumors. Cancer Lett. 2003, 199:69-73.
38. Türköz H.K., Oksüz H., Yurdakul Z., Ozcan D. Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr. Pathol. 2008, 19:92-96.
39. Vogel C., Marcotte E.M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 2012, 13:227-232.
40. Warfield P.R., Makkar P.N., Raz A., Ochieng J. Adhesion of human breast carcinoma to extracellular matrix proteins is modulated by galectin-3. Invasion Metastasis 1997, 17:101-112.
41. Weir H.K., Thun M.J., Hankey B.F., Ries L.A., Howe H.L., Wingo P.A., Jemal A., Ward E., Anderson R.N., Edwards B.K. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J. Natl. Cancer Inst. 2003, 95:1276-1299.
42. Wu G., Wang J., Zhou Z., Li T., Tang F. Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity?. J. Int. Med. Res. 2013, 41:975-983.
43. Xu X.C., el-Naggar A.K., Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am. J. Pathol. 1995, 147:815-822.
44. Yang R.Y., Hsu D.K., Yu L., Ni J., Liu F.T. Cell cycle regulation by galectin-12, a new member of the galectin superfamily. J. Biol. Chem. 2001, 276:20252-20260.
45. Zhang Z.Y., Dong J.H., Chen Y.W., Wang X.Q., Li C.H., Wang J., Wang G.Q., Li H.L., Wang X.D. Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. Asian Pac. J. Cancer Prev. 2012, 13:2503-2509.